myPBCteam

Iqirvo (elafibranor) is one of the newest FDA-approved treatments for PBC, receiving approval in June 2024. It works differently from other PBC medications by blocking bile acid production, which is one of the underlying mechanisms of PBC. In clinical trials, Iqirvo showed promising results by reducing alkaline phosphatase Show Full Answer

Iqirvo (elafibranor) is one of the newest FDA-approved treatments for PBC, receiving approval in June 2024. It works differently from other PBC medications by blocking bile acid production, which is one of the underlying mechanisms of PBC. In clinical trials, Iqirvo showed promising results by reducing alkaline phosphatase (ALP) levels in PBC patients. Since Iqirvo is such a new medication, many patients are just beginning to try it. It's important to discuss potential side effects and treatment options with your healthcare provider, who can help determine if Iqirvo might be right for your specific situation. They can also monitor your response to the medication and adjust your treatment plan as needed.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

PBC Stages and Symptoms: Understanding the Progression

Primary Biliary Cholangitis Treatments and Their Side Effects